scholarly journals A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial

2013 ◽  
Vol 2 (3) ◽  
pp. 360-366 ◽  
Author(s):  
Siow Ming Lee ◽  
Allan Hackshaw
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Trial Design ◽  
Tumor Response ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Early Tumor Response ◽  
Early Tumor

scholarly journals Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Menno Tamminga ◽  
Sanne de Wit ◽  
T. Jeroen N. Hiltermann ◽  
Wim Timens ◽  
Ed Schuuring ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Tumor Response ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals P2.01-90 PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients with or without EGFR Mutation

2018 ◽  
Vol 13 (10) ◽  
pp. S699-S700
Author(s):  
T. Siripoon ◽  
P. Incharoen ◽  
N. Trachu ◽  
D. Munthum ◽  
K. Kamprerasart ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals PD-L2 expression as a predictive biomarker for the response to anti-PD-1 drugs in non-small cell lung cancer patients

2018 ◽  
Vol 29 ◽  
pp. vii81
Author(s):  
Shinkichi Takamori ◽  
Kazuki Takada ◽  
Gouji Toyokawa ◽  
Koichi Azuma ◽  
Tomoko Jogo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Abstract 3592: Association ofSUMO-1 andUBC9 genotypes with tumor response and toxicity in non-small cell lung cancer patients treated with irinotecan-based chemotherapy

2010 ◽  
Author(s):  
Ji-Youn Han ◽  
Geon Kook Lee ◽  
Sun Young Yoo ◽  
Sung Jin Yoon ◽  
Heung Tae Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Tumor Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Predictive biomarker of response to anti-PD-1 treatment in non-small cell lung cancer patients.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 148-148
Author(s):  
Xuan Zheng ◽  
Yi Hu ◽  
Junxun Ma ◽  
Fan Zhang ◽  
Danyang Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Response Evaluation ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Significant Difference ◽  
Nsclc Patients

148 Background: PD-1 inhibitors have shown significant clinical activity in different cancer types. However, responses in pts with NSCLC are variable, and insights are needed to identify a predictive biomarker of response with greater diagnostic accuracy. Here we tested the hypothesis tha tserum TNF-a level is predictive of response to anti-PD-1 treatment. Methods: NSCLC patients treated with nivolumab or pembrolizumab were studied. Pts received nivolumab (3mg/kg, q2w) or pembrolizumab ( 2mg/kg, q3w). Pts on anti-PD1 were classified as either responders (R) deriving clinical benefit (with SD, PR, CR) or non-responders (NR) not deriving clinical benefit (PD) based on RECIST criteria.Serum was collected at baseline; at 2-3 weeks after the first dose (early stage); and at the time of response evaluation. Serum TNF-a levels were determined by Luminex kit. Changes in serum TNF-a levels and their strength of association with response were compared with Non-parametric Analysis. Results: Evaluable plasma samples were collected from twenty-one NSCLC patients treated with nivolumab or pembrolizumab. There was no significant difference in baseline serum TNF-a levels in responders (n = 15) vs non-responders (n = 6). Between baseline and early stage ,serum TNF-a levels significantly increased in responders (P = 0.010), while in non-responders, no significant change was found. High early change rate of serum TNF-a levels ( > 50%) was observed only in responders(n = 7).At early stage, responders had significantly higher serum TNF-a levels than non-responders(P = 0.008). We found no significant difference in serum TNF-a levels at the time of response evaluation. Conclusions: Early changes in serum TNF-a levels and high serum TNF-a levels at early stage in non-small cell lung cancer patients correlate to response to anti-PD-1 treatment.

Sign in / Sign up

Export Citation Format

Share Document